About Us Image
About Us
Meet the Team
Lisa Burns
President and Chief Executive Officer


Justin W. Jackson
Executive Vice President, Director, Life Sciences Practice


Angeli Kolhatkar
Senior Vice President, Investor Relations


Kimberly Minarovich
Vice President, Investor Relations


Ami Bavishi
Account Manager, Investor Relations


Nancy Yu
Account Manager, Investor Relations


Melissa Forst
Senior Account Executive


Lisa Burns

President and Chief Executive Officer of Burns McClellan, Inc.


Lisa Burns is the President and Chief Executive Officer of Burns McClellan, Inc., the country's oldest independent healthcare public and investor relations firm. Since its establishment in 1988, the agency has represented more than 200 of the industry's pharmaceutical and biotechnology concerns, through all phases of development and commercialization. Syntex Corporation, Rh么ne-Poulenc Rorer, Wyeth-Ayerst, Novartis, Hoffmann-La Roche, Glaxo Wellcome PLC, Bayer, Baxter, Gilead Sciences, Human Genome Sciences, Alkermes, COR Therapeutics, Cephalon, Vicuron, GelTex and Affymetrix are among the industry's leaders that have retained Burns McClellan. Specifically, Burns McClellan provides investor and public relations services to pharmaceutical, biotechnology, drug delivery, and device companies both domestically and globally. The agency has extensive expertise in providing strategic guidance in the areas of financial, scientific and regulatory communications, as well as crisis and issues management. Burns McClellan has offices in New York and San Francisco.

Over the past two decades, Ms. Burns has provided strategic financial counsel to both early- and late-stage companies, with a particular focus on securing access to institutional investors, and has well-established relationships with the leading venture capitalists investing in the life sciences sector. She has been instrumental in assisting early-stage companies with strategic positioning in the fund raising process, from seed rounds through initial public offerings, and subsequent financings.

In the communications area, Ms. Burns' expertise includes investor and media relations, corporate development and strategic consulting, new product launches, and crisis management. Ms. Burns has worked on product development and issues management in such areas as women's healthcare, neurology, oncology, hematology, cardiology and obesity/metabolic disorders.

Ms. Burns served as a member of the Board of Directors of Genesis Pharmaceuticals and was a board member of Sapient Health Network (currently a division of Web MD/Healtheon). Ms. Burns was a founding member of the Society for the Advancement of Women's Health Research (SAWHR), and the founder of its corporate advisory council. Prior to founding Burns McClellan, Ms. Burns served ten years as a member of senior management at several leading public relations firms, including Fleishman-Hillard International Communications, Edelman Public Relations Worldwide, and Burson-Marstellar.

Ms. Burns has written several published articles regarding life sciences innovation and is a contributing author to "From the Bench to the Street." She is frequently asked to address audiences at some of the most well respected life sciences conferences. Recently, she has spoken at the Healthcare CEO Summit 2005 (sponsored by KPBC and Domain), as well as the Annual Limited Partner Meetings & CEO Conference sponsored by Tullis Dickerson & Co., Inc.

Ms. Burns attended Vassar College and New York University.